JP2025072437A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2025072437A5 JP2025072437A5 JP2025014511A JP2025014511A JP2025072437A5 JP 2025072437 A5 JP2025072437 A5 JP 2025072437A5 JP 2025014511 A JP2025014511 A JP 2025014511A JP 2025014511 A JP2025014511 A JP 2025014511A JP 2025072437 A5 JP2025072437 A5 JP 2025072437A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- pharmaceutical composition
- use according
- seq
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762471190P | 2017-03-14 | 2017-03-14 | |
| US62/471,190 | 2017-03-14 | ||
| US201762553059P | 2017-08-31 | 2017-08-31 | |
| US62/553,059 | 2017-08-31 | ||
| PCT/US2018/022462 WO2018170145A1 (en) | 2017-03-14 | 2018-03-14 | Methods for treating complement-mediated diseases and disorders |
| JP2019550688A JP7293122B2 (ja) | 2017-03-14 | 2018-03-14 | 補体が媒介する疾患および障害を処置するための方法 |
| JP2023030606A JP2023071824A (ja) | 2017-03-14 | 2023-03-01 | 補体が媒介する疾患および障害を処置するための方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023030606A Division JP2023071824A (ja) | 2017-03-14 | 2023-03-01 | 補体が媒介する疾患および障害を処置するための方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025072437A JP2025072437A (ja) | 2025-05-09 |
| JP2025072437A5 true JP2025072437A5 (cg-RX-API-DMAC7.html) | 2026-01-20 |
Family
ID=61873979
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019550688A Active JP7293122B2 (ja) | 2017-03-14 | 2018-03-14 | 補体が媒介する疾患および障害を処置するための方法 |
| JP2023030606A Pending JP2023071824A (ja) | 2017-03-14 | 2023-03-01 | 補体が媒介する疾患および障害を処置するための方法 |
| JP2025014511A Pending JP2025072437A (ja) | 2017-03-14 | 2025-01-31 | 補体が媒介する疾患および障害を処置するための方法 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019550688A Active JP7293122B2 (ja) | 2017-03-14 | 2018-03-14 | 補体が媒介する疾患および障害を処置するための方法 |
| JP2023030606A Pending JP2023071824A (ja) | 2017-03-14 | 2023-03-01 | 補体が媒介する疾患および障害を処置するための方法 |
Country Status (14)
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014066744A2 (en) | 2012-10-25 | 2014-05-01 | True North Therapeutics, Inc. | Anti-complement c1s antibodies and uses thereof |
| ES2912396T3 (es) | 2012-11-02 | 2022-05-25 | Bioverativ Usa Inc | Anticuerpos anti-C1s del complemento y uso de los mismos |
| EP4212175A1 (en) | 2015-04-06 | 2023-07-19 | Bioverativ USA Inc. | Humanized anti-c1s antibodies and methods of use thereof |
| IL326479A (en) | 2016-10-12 | 2026-04-01 | Bioverativ Usa Inc | Anti-c1s antibodies and methods of use thereof |
| PL3893924T3 (pl) | 2018-12-13 | 2025-01-13 | argenx BV | Przeciwciała przeciwko ludzkiemu czynnikowi c2b dopełniacza i sposoby zastosowania |
| GB2584105B (en) * | 2019-05-21 | 2023-08-02 | Argenx Bvba | Methods of treating neuropathy |
| JP2023503611A (ja) * | 2019-11-26 | 2023-01-31 | オメロス コーポレーション | 造血幹細胞移植に関連する特発性肺炎症候群（ｉｐｓ）および／または毛細血管漏出症候群（ｃｌｓ）および／または生着症候群（ｅｓ）および／または体液過剰（ｆｏ）を治療および／または予防するための方法 |
| FI129383B (en) | 2020-06-15 | 2022-01-31 | Faron Pharmaceuticals Oy | Stable anti-clever-1 antibody formulation |
| BR112023001942A2 (pt) * | 2020-08-06 | 2023-02-28 | Bioverativ Usa Inc | Citocinas inflamatórias e fadiga em indivíduo com doença mediada por complemento |
| TW202304508A (zh) | 2021-03-31 | 2023-02-01 | 美商百歐維拉提夫美國公司 | 減少冷凝集素疾病患者之手術相關溶血 |
| US12252550B2 (en) | 2021-05-20 | 2025-03-18 | Dianthus Therapeutics Opco, Inc. | Antibodies that bind to C1S and uses thereof |
| CN117642431B (zh) | 2021-07-13 | 2025-07-15 | 迈威(美国)生物治疗有限公司 | 抗c1s抗体和其用途 |
| CN114874329A (zh) * | 2022-05-19 | 2022-08-09 | 江苏大学 | 一种补体活化C1s酶荧光检测试剂盒及检测方法与应用 |
| MA71249A (fr) | 2022-06-24 | 2025-04-30 | Bioverativ Usa Inc. | Méthodes de traitement de maladies médiées par complément |
| TW202426490A (zh) | 2022-11-21 | 2024-07-01 | 美商黛安瑟斯醫療運營公司 | 結合ｃ１ｓ之抗體及其用途 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| JPH02500329A (ja) | 1987-05-21 | 1990-02-08 | クリエイテイブ・バイオマリキユールズ・インコーポレーテツド | ターゲット化多機能蛋白質 |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| JP3540315B2 (ja) | 1991-09-23 | 2004-07-07 | メディカル リサーチ カウンシル | キメラ抗体の製造−組合せアプローチ |
| DE69233528T2 (de) | 1991-11-25 | 2006-03-16 | Enzon, Inc. | Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen |
| DE614989T1 (de) | 1993-02-17 | 1995-09-28 | Morphosys Proteinoptimierung | Verfahren für in vivo Selektion von Ligandenbindende Proteine. |
| ES2912396T3 (es) * | 2012-11-02 | 2022-05-25 | Bioverativ Usa Inc | Anticuerpos anti-C1s del complemento y uso de los mismos |
| WO2015084999A1 (en) * | 2013-12-06 | 2015-06-11 | True North Therapeutics, Inc. | Complement component biomarker assays |
-
2018
- 2018-03-14 SG SG11201907583TA patent/SG11201907583TA/en unknown
- 2018-03-14 KR KR1020197029545A patent/KR102934707B1/ko active Active
- 2018-03-14 BR BR112019018950-5A patent/BR112019018950A2/pt unknown
- 2018-03-14 CA CA3055781A patent/CA3055781A1/en active Pending
- 2018-03-14 KR KR1020267006425A patent/KR20260039796A/ko active Pending
- 2018-03-14 TW TW107108658A patent/TWI848905B/zh active
- 2018-03-14 EP EP18715381.2A patent/EP3596121A1/en active Pending
- 2018-03-14 AU AU2018236267A patent/AU2018236267B2/en active Active
- 2018-03-14 MX MX2019010994A patent/MX2019010994A/es unknown
- 2018-03-14 US US16/494,267 patent/US20210115116A1/en not_active Abandoned
- 2018-03-14 WO PCT/US2018/022462 patent/WO2018170145A1/en not_active Ceased
- 2018-03-14 TW TW113122096A patent/TW202513092A/zh unknown
- 2018-03-14 IL IL269174A patent/IL269174B2/en unknown
- 2018-03-14 CN CN201880029619.1A patent/CN110753701A/zh active Pending
- 2018-03-14 JP JP2019550688A patent/JP7293122B2/ja active Active
- 2018-03-14 CR CR20190468A patent/CR20190468A/es unknown
- 2018-03-14 IL IL325084A patent/IL325084A/en unknown
-
2019
- 2019-09-13 MX MX2025010483A patent/MX2025010483A/es unknown
-
2023
- 2023-03-01 JP JP2023030606A patent/JP2023071824A/ja active Pending
-
2025
- 2025-01-31 JP JP2025014511A patent/JP2025072437A/ja active Pending
- 2025-06-12 AU AU2025204392A patent/AU2025204392A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023113696A5 (cg-RX-API-DMAC7.html) | ||
| AU2022215307B2 (en) | Methods of treating autoimmune and alloimmune disorders | |
| CN114891100B (zh) | 抗N3pGlu淀粉样蛋白β肽抗体及其用途 | |
| JP2020511469A5 (cg-RX-API-DMAC7.html) | ||
| JP2020124199A5 (cg-RX-API-DMAC7.html) | ||
| TWI669314B (zh) | 針對ｔａｕ之抗體及其用途 | |
| EP2445937B1 (en) | Bispecific antibodies that bind to complement proteins | |
| CN104822389B (zh) | 识别α-突触核蛋白的抗体 | |
| US9243060B2 (en) | Humanized anti-factor C3b antibodies and uses thereof | |
| JP2018519810A5 (cg-RX-API-DMAC7.html) | ||
| JP2014502141A5 (cg-RX-API-DMAC7.html) | ||
| IL266911B1 (en) | Anti-tau antibodies and uses thereof in treating tauopathy, retaining or increasing cognitive memory capacity or slowing memory loss | |
| TW202243690A (zh) | 抗N3pGlu類澱粉β抗體及其用途 | |
| JP2018501813A5 (cg-RX-API-DMAC7.html) | ||
| JP2024020446A (ja) | 抗ｃ５抗体組み合わせ物およびその使用 | |
| TW202140560A (zh) | 抗ＦｃＲｎ抗體、其抗原結合片段及其醫藥用途 | |
| Samson et al. | Diagnostic strategy for patients with hypogammaglobulinemia in rheumatology | |
| US20220064272A1 (en) | Anti-tauc3 antibodies and uses thereof | |
| JP2024504366A5 (cg-RX-API-DMAC7.html) | ||
| TW202300518A (zh) | 抗N3pGlu類澱粉β抗體及其用途 | |
| EP3630819A1 (en) | Dosage and administration of anti-c5 antibodies for treatment of protein-losing enteropathy in patients | |
| CN106519031A (zh) | 一种与旁路途径相关的cfh抗体 | |
| Rahman et al. | Anti-DNA antibodies—structure and function | |
| CN117279938A (zh) | 抗-N3pGlu淀粉样蛋白β抗体及其用途 | |
| Preul et al. | Cerebral involvement in a patient with Goodpasture's disease due to shortened induction therapy: a case report |